Details

Autor(en) / Beteiligte

• Palumbo, Antonio
• Anderson, Kenneth

Titel

Multiple Myeloma

Ist Teil von

• The New England journal of medicine, 2011-03, Vol.364 (11), p.1046-1060

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• Autologous stem-cell transplantation and agents such as thalidomide, lenalidomide, and bortezomib have changed the management of myeloma and extended overall survival. This review discusses both the biologic features and the management of multiple myeloma. Multiple myeloma is a neoplastic plasma-cell disorder that is characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction. 1 It accounts for approximately 1% of neoplastic diseases and 13% of hematologic cancers. In Western countries, the annual age-adjusted incidence is 5.6 cases per 100,000 persons. 2 The median age at diagnosis is approximately 70 years; 37% of patients are younger than 65 years, 26% are between the ages of 65 and 74 years, and 37% are 75 years of age or older. 2 , 3 In recent years, the . . .